TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Provided By GlobeNewswire
Last update: Aug 4, 2025
Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million
Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million
Read more at globenewswire.com
